Publications
SCOPE: A Normalization and Copy-Number Estimation Method for Single-Cell DNA Sequencing." Cell Syst 10, no. 5 (2020): 445-452.e6.
"Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
"Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm." Stat Med 32, no. 12 (2013): 2140-54.
"Sample size determination in shared frailty models for multivariate time-to-event data." J Biopharm Stat 24, no. 4 (2014): 908-23.
"Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes." Genet Epidemiol 37, no. 3 (2013): 276-82.
"Sample size calculation for studies with grouped survival data." Stat Med 37, no. 27 (2018): 3904-3917.
"On sample size calculation for comparing survival curves under general hypothesis testing." J Biopharm Stat 22, no. 3 (2012): 485-95.
"Sample size calculation for cluster randomization trials with a time-to-event endpoint." Stat Med 39, no. 25 (2020): 3608-3623.
"Sample size and power determination in joint modeling of longitudinal and survival data." Stat Med 30, no. 18 (2011): 2295-309.
"SAFE-clustering: Single-cell Aggregated (from Ensemble) clustering for single-cell RNA-seq data." Bioinformatics 35, no. 8 (2019): 1269-1277.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"Robust test method for time-course microarray experiments." BMC Bioinformatics 11 (2010): 391.
"Robust Score Tests With Missing Data in Genomics Studies." J Am Stat Assoc 114, no. 528 (2019): 1778-1786.
"Robust regression for optimal individualized treatment rules." Stat Med 38, no. 11 (2019): 2059-2073.
"Robust Multicategory Support Vector Machines using Difference Convex Algorithm." Math Program 169, no. 1 (2018): 277-305.
"A robust method for estimating optimal treatment regimes." Biometrics 68, no. 4 (2012): 1010-8.
"Robust learning for optimal treatment decision with NP-dimensionality." Electron J Stat 10 (2016): 2894-2921.
"Robust kernel association testing (RobKAT)." Genet Epidemiol 44, no. 3 (2020): 272-282.
"Robust estimation of optimal dynamic treatment regimes for sequential treatment decisions." Biometrika 100, no. 3 (2013).
"Risk calculators are useful but..." J Thorac Cardiovasc Surg 151, no. 3 (2016): 706-707.
"Reweighted estimators for additive hazard model with censoring indicators missing at random." Lifetime Data Anal 24, no. 2 (2018): 224-249.
"Responses to discussants of 'Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group'." Stat Med 34, no. 14 (2015): 2202-3.
"Response to reader reaction." Biometrics 71, no. 1 (2015): 267-273.
"Residual Weighted Learning for Estimating Individualized Treatment Rules." J Am Stat Assoc 112, no. 517 (2017): 169-187.
"Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017).
"On the relative efficiency of using summary statistics versus individual-level data in meta-analysis." Biometrika 97, no. 2 (2010): 321-332.
"Rejoinder to "A note on testing and estimation in marker-set association study using semiparametric quantile regression kernel machine"." Biometrics 74, no. 2 (2018): 767-768.
"Reinforcement Learning Trees." J Am Stat Assoc 110, no. 512 (2015): 1770-1784.
"Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
"Reinforced Angle-based Multicategory Support Vector Machines." J Comput Graph Stat 25, no. 3 (2016): 806-825.
"A regularized variable selection procedure in additive hazards model with stratified case-cohort design." Lifetime Data Anal 24, no. 3 (2018): 443-463.
"Regression Models on Riemannian Symmetric Spaces." J R Stat Soc Series B Stat Methodol 79, no. 2 (2017): 463-482.
"A regression approach to ROC surface, with applications to Alzheimer's disease." Sci China Math 55, no. 8 (2012): 1583-1595.
"Regression analysis of sparse asynchronous longitudinal data." J R Stat Soc Series B Stat Methodol 77, no. 4 (2015): 755-776.
"Regression analysis for secondary response variable in a case-cohort study." Biometrics 74, no. 3 (2018): 1014-1022.
"Reexamining Dis/Similarity-Based Tests for Rare-Variant Association with Case-Control Samples." Genetics 209, no. 1 (2018): 105-113.
"Recursively Imputed Survival Trees." J Am Stat Assoc 107, no. 497 (2012): 331-340.
"Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82.
"Receiver operating characteristic curves and confidence bands for support vector machines." Biometrics 77, no. 4 (2021): 1422-1430.
"Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level." PLoS Comput Biol 12, no. 6 (2016): e1004993.
"The rapid enrollment design for Phase I clinical trials." Stat Med 35, no. 15 (2016): 2516-24.
"Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups." J Biopharm Stat 29, no. 4 (2019): 625-634.
"Rapid and robust resampling-based multiple-testing correction with application in a genome-wide expression quantitative trait loci study." Genetics 190, no. 4 (2012): 1511-20.
"Randomized phase II clinical trials." J Biopharm Stat 24, no. 4 (2014): 802-16.
"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
"On random sample size, ignorability, ancillarity, completeness, separability, and degeneracy: sequential trials, random sample sizes, and missing data." Stat Methods Med Res 23, no. 1 (2014): 11-41.
"Random Effects Model for Multiple Pathway Analysis with Applications to Type II Diabetes Microarray Data." Stat Biosci 7, no. 2 (2015): 167-186.
"Radiomics analysis using stability selection supervised component analysis for right-censored survival data." Comput Biol Med 124 (2020): 103959.
"Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer." Am J Mens Health 10, no. 5 (2016): 399-407.
"Quantitative trait analysis in sequencing studies under trait-dependent sampling." Proc Natl Acad Sci U S A 110, no. 30 (2013): 12247-52.
"Quantile-Optimal Treatment Regimes." J Am Stat Assoc 113, no. 523 (2018): 1243-1254.
"Quantile Regression Models for Current Status Data." J Stat Plan Inference 178 (2016): 112-127.
"On Quantile Regression in Reproducing Kernel Hilbert Spaces with Data Sparsity Constraint." J Mach Learn Res 17, no. 40 (2016): 1-45.
"Quantile regression for censored mixed-effects models with applications to HIV studies." Stat Interface 8, no. 2 (2015): 203-215.
"Quantifying the Impact of Non-coding Variants on Transcription Factor-DNA Binding." Res Comput Mol Biol 10229 (2017): 336-352.
"Quantifying the average of the time-varying hazard ratio via a class of transformations." Lifetime Data Anal 21, no. 2 (2015): 259-79.
"Quantifying center of pressure variability in chondrodystrophoid dogs." Vet J 226 (2017): 26-31.
"Q-LEARNING WITH CENSORED DATA." Ann Stat 40, no. 1 (2012): 529-560.
"Q- and A-learning Methods for Estimating Optimal Dynamic Treatment Regimes." Stat Sci 29, no. 4 (2014): 640-661.
"P-Value Precision and Reproducibility." Am Stat 65, no. 4 (2011): 213-221.
"Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer." Clin Cancer Res 26, no. 1 (2020): 82-92.
"Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer." Cancer 121, no. 6 (2015): 836-43.
"Prospects and challenges for clinical decision support in the era of big data." JCO Clin Cancer Inform 2 (2018).
"Proportional hazards model with a change point for clustered event data." Biometrics 73, no. 3 (2017): 835-845.
"Proportional exponentiated link transformed hazards (ELTH) models for discrete time survival data with application." Lifetime Data Anal 22, no. 1 (2016): 38-62.
"Properties of Estimators in Exponential Family Settings with Observation-based Stopping Rules." J Biom Biostat 7, no. 1 (2016).
"Proper Use of Allele-Specific Expression Improves Statistical Power for -eQTL Mapping with RNA-Seq Data." J Am Stat Assoc 110, no. 511 (2015): 962-974.
"Proper Inference for Value Function in High-Dimensional Q-Learning for Dynamic Treatment Regimes." J Am Stat Assoc 114, no. 527 (2019): 1404-1417.
"Probability-enhanced sufficient dimension reduction for binary classification." Biometrics 70, no. 3 (2014): 546-55.
"Principal Components Adjusted Variable Screening." Comput Stat Data Anal 110 (2017): 134-144.
"PreMeta: a tool to facilitate meta-analysis of rare-variant associations." BMC Genomics 18, no. 1 (2017): 160.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Predictive accuracy of markers or risk scores for interval censored survival data." Stat Med 39, no. 18 (2020): 2437-2446.
"Predictive accuracy of covariates for event times." Biometrika 99, no. 3 (2012): 615-630.
"Prediction of cancer drug sensitivity using high-dimensional omic features." Biostatistics 18, no. 1 (2017): 1-14.
"Prediction of a time-to-event trait using genome wide SNP data." BMC Bioinformatics 14 (2013): 58.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data." J Alzheimers Dis 46, no. 3 (2015): 695-702.
"Precision Medicine Approach to Develop and Internally Validate Optimal Exercise and Weight-Loss Treatments for Overweight and Obese Adults With Knee Osteoarthritis: Data From a Single-Center Randomized Trial." Arthritis Care Res (Hoboken) 73, no. 5 (2021): 693-701.
"Precision Medicine." Annu Rev Stat Appl 6 (2019): 263-286.
"Practical designs for Phase I combination studies in oncology." J Biopharm Stat 26, no. 1 (2016): 150-66.
"A practical Bayesian adaptive design incorporating data from historical controls." Stat Med 37, no. 27 (2018): 4054-4070.
"A Powerful Test for SNP Effects on Multivariate Binary Outcomes using Kernel Machine Regression." Stat Biosci 10, no. 1 (2018): 117-138.
"The power prior: theory and applications." Stat Med 34, no. 28 (2015): 3724-49.
"Power and sample size calculations for SNP association studies with censored time-to-event outcomes." Genet Epidemiol 36, no. 6 (2012): 538-48.
"Power and sample size calculation for microarray studies." J Biopharm Stat 22, no. 1 (2012): 30-42.
"Posterior Contraction Rates of the Phylogenetic Indian Buffet Processes." Bayesian Anal 11, no. 2 (2016): 477-497.
"Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol 35, no. 25 (2017): 2885-2892.
"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint." Med Res Arch 5, no. 7 (2017).
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16.
"Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28.
"Phase II cancer clinical trials for biomarker-guided treatments." J Biopharm Stat 28, no. 2 (2018): 256-263.
"Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity." Pharmacogenomics 14, no. 2 (2013): 205-13.
"Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy." Pharmacogenomics 14, no. 5 (2013): 555-74.
"PERTURBATION AND SCALED COOK'S DISTANCE." Ann Stat 40, no. 2 (2012): 785-811.
"Personalized Evaluation of Biomarker Value: A Cost-Benefit Perspective." Stat Biosci 8, no. 1 (2016): 43-65.
"Personalized Dose Finding Using Outcome Weighted Learning." J Am Stat Assoc 111, no. 516 (2016): 1509-1521.
"permGPU: Using graphics processing units in RNA microarray association studies." BMC Bioinformatics 11 (2010): 329.
"